Agile Therapeutics, Inc. to Present at Elsevier Business Intelligence's Therapeutic Area Partnerships
Published: Nov 29, 2012
PRINCETON, NJ--(Marketwire - November 29, 2012) -
Mr. Altomari's presentation will provide an overview of the Company's recent milestones, its pipeline of products, and its growth strategy. Agile's lead investigational product is AG200-15, which is designed to be a once-weekly, low-dose contraceptive patch. The Company recently filed the NDA for AG200-15, and anticipates a response in 2013.
Elsevier considered various criteria when selecting the Top 10 Hot Space Projects to Watch, including the strength of the science behind the company's product(s), the market size for the company's product(s), and the unmet need for the company's product(s).
"It is an honor to be selected as a top project to watch by Elsevier," said Mr. Altomari. "We are proud of the work we have done in developing AG200-15, and we look forward to discussing this progress, as well as our pipeline of products and future plans, at Therapeutic Area Partnerships."
AG200-15 is an investigational combination hormonal contraceptive patch, designed to deliver a low dose of ethinyl estradiol comparable to low-dose combination oral contraceptives. The phase III trials for AG200-15 enrolled nearly 2,000 women and formed the basis for the Company's application to the US Food and Drug Administration in 2012.
The AG200-15 patch is intended to be applied once weekly for three weeks, followed by a fourth, patch-free week. The patch is designed using a soft, flexible cloth, with a silky feel, and is intended to provide excellent adhesion, comfort, and appearance.
About Agile Therapeutics
Agile Therapeutics is a pharmaceutical development company specializing in Women's Healthcare products, with an initial focus on providing women with more options and potentially more convenient methods of hormonal contraception. The Company's lead investigational product, AG200-15, is designed to be a once-weekly contraceptive patch that has recently been submitted to the FDA as a New Drug Application (NDA) for review. In addition, Agile is also developing a low dose, progestin-only contraceptive patch, AG890 (formerly AG900). Both AG200-15 and AG890 incorporate proprietary transdermal delivery technology, Skinfusion®, developed by Agile, consisting of an active and peripheral adhesive system that has been designed to allow stable drug delivery and dependable adhesion over seven days. For more information, please visit http://www.agiletherapeutics.com.
About Elsevier Business Intelligence
Elsevier Business Intelligence, a global leader in the field of healthcare industry information, provides business intelligence on regulatory, business and reimbursement issues that are vital to the healthcare industry. Through a range of products including publications, conferences, e-learning, databases and reports, Elsevier Business Intelligence places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge, by providing the perfect combination of news and information together with penetrating insight and analysis. Our leading publications include PharmAsia News, IN VIVO and "The Pink Sheet." For more information, visit: http://www.ElsevierBi.com.
Chantal Beaudry/Karen Famighetti for Agile Therapeutics